Other · developed by Janux Therapeutics
JANX011 is a drug administered subcutaneously as a single dose. It is studied in autoimmune conditions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07291323 | Early Phase 1 | Autoimmune | Recruiting | JANX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autoimmune
Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.
See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JANX catalysts and pipeline →